{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:01:57Z","timestamp":1790125317529,"version":"4.0.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Operational Programme \u201cCompetitiveness, Entrepreneurship and Innovation\u201d","award":["project code T2EDK-02361, MIS 5067590"],"award-info":[{"award-number":["project code T2EDK-02361, MIS 5067590"]}]},{"name":"Pancretan Health Association"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-58152-3","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:05:30Z","timestamp":1782482730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Differential functional and lipidomic impact of tofacitinib and other disease-modifying antirheumatic drugs on HDL in rheumatoid arthritis"],"prefix":"10.1038","volume":"16","author":[{"given":"Eftaxia-Konstantina","family":"Valanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia-Georgia","family":"Dedemadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Simopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Goutakoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Sevdali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Ruhanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Holopainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"House","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reijo","family":"K\u00e4kel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prodromos","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3107-1189","authenticated-orcid":false,"given":"Angeliki","family":"Chroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"58152_CR1","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","volume":"71","author":"JA Avina-Zubieta","year":"2012","unstructured":"Avina-Zubieta, J. A., Thomas, J., Sadatsafavi, M., Lehman, A. J. & Lacaille, D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann. Rheum. Dis. 71, 1524\u20131529 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"58152_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1093\/rheumatology\/kes243","volume":"52","author":"KP Liao","year":"2013","unstructured":"Liao, K. P. & Solomon, D. H. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) 52, 45\u201352 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"58152_CR3","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/ard.2010.135871","volume":"70","author":"E Myasoedova","year":"2011","unstructured":"Myasoedova, E. et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann. Rheum. Dis. 70, 482\u2013487 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"58152_CR4","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","volume":"44","author":"A von Eckardstein","year":"2023","unstructured":"von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T. & Catapano, A. L. High-density lipoprotein revisited: biological functions and clinical relevance. Eur. Heart J. 44, 1394\u20131407 (2023).","journal-title":"Eur. Heart J."},{"key":"58152_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2020.04.015","volume":"302","author":"MT Soria-Florido","year":"2020","unstructured":"Soria-Florido, M. T., Schroder, H., Grau, M., Fito, M. & Lassale, C. High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis. Atherosclerosis 302, 36\u201342 (2020).","journal-title":"Atherosclerosis"},{"key":"58152_CR6","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/art.21976","volume":"54","author":"M McMahon","year":"2006","unstructured":"McMahon, M. et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54, 2541\u20132549 (2006).","journal-title":"Arthritis Rheum."},{"key":"58152_CR7","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2011-200493","volume":"71","author":"C Charles-Schoeman","year":"2012","unstructured":"Charles-Schoeman, C. et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 71, 1157\u20131162 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"58152_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/annrheumdis-2012-202914","volume":"73","author":"N Ronda","year":"2014","unstructured":"Ronda, N. et al. Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann. Rheum. Dis. 73, 609\u2013615 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"58152_CR9","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.3390\/antiox11122317","volume":"11","author":"GL Erre","year":"2022","unstructured":"Erre, G. L. et al. Association between Paraoxonase\/Arylesterase Activity of Serum PON-1 Enzyme and Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Antioxidants 11, 2317 (2022).","journal-title":"Antioxidants"},{"key":"58152_CR10","doi-asserted-by":"publisher","first-page":"151943","DOI":"10.1016\/j.semarthrit.2021.12.011","volume":"52","author":"J Zhou","year":"2022","unstructured":"Zhou, J., Dai, Y., Lin, Y. & Chen, K. Association between serum amyloid A and rheumatoid arthritis: A systematic review and meta-analysis. Semin. Arthritis Rheum. 52, 151943 (2022).","journal-title":"Semin. Arthritis Rheum."},{"key":"58152_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12944-021-01444-6","volume":"20","author":"B Xie","year":"2021","unstructured":"Xie, B., He, J., Liu, Y., Liu, T. & Liu, C. A meta-analysis of HDL cholesterol efflux capacity and concentration in patients with rheumatoid arthritis. Lipids Health Dis. 20, 18 (2021).","journal-title":"Lipids Health Dis."},{"key":"58152_CR12","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1097\/RHU.0000000000001657","volume":"28","author":"F Cacciapaglia","year":"2022","unstructured":"Cacciapaglia, F. et al. The Impact of Biologic Drugs on High-Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients. J. Clin. Rheumatol. 28, e145\u2013e149 (2022).","journal-title":"J. Clin. Rheumatol."},{"key":"58152_CR13","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1136\/ard.2008.092171","volume":"68","author":"C Popa","year":"2009","unstructured":"Popa, C. et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann. Rheum. Dis. 68, 868\u2013872 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"58152_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/art.39833","volume":"69","author":"C Charles-Schoeman","year":"2017","unstructured":"Charles-Schoeman, C. et al. Improvement of high-density lipoprotein function in patients with early rheumatoid arthritis treated with methotrexate monotherapy or combination therapies in a randomized controlled trial. Arthritis & Rheumatology 69, 46\u201357 (2017).","journal-title":"Arthritis & Rheumatology"},{"key":"58152_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12967-021-03169-7","volume":"19","author":"H Luan","year":"2021","unstructured":"Luan, H. et al. Serum metabolomic and lipidomic profiling identifies diagnostic biomarkers for seropositive and seronegative rheumatoid arthritis patients. J. Transl. Med. 19, 500 (2021).","journal-title":"J. Transl. Med."},{"key":"58152_CR16","doi-asserted-by":"publisher","first-page":"1410365","DOI":"10.3389\/fimmu.2024.1410365","volume":"15","author":"R Li","year":"2024","unstructured":"Li, R., Koh, J. H., Park, W. J., Choi, Y. & Kim, W. U. Serum and urine lipidomic profiles identify biomarkers diagnostic for seropositive and seronegative rheumatoid arthritis. Front. Immunol. 15, 1410365 (2024).","journal-title":"Front. Immunol."},{"key":"58152_CR17","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.atherosclerosis.2014.09.034","volume":"237","author":"L Gomez Rosso","year":"2014","unstructured":"Gomez Rosso, L. et al. Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: relevance of inflammation. Atherosclerosis 237, 652\u2013660 (2014).","journal-title":"Atherosclerosis"},{"key":"58152_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s13105-019-00694-4","volume":"75","author":"C Giraud","year":"2019","unstructured":"Giraud, C. et al. Alterations of HDL particle phospholipid composition and role of inflammation in rheumatoid arthritis. J. Physiol. Biochem. 75, 453\u2013462 (2019).","journal-title":"J. Physiol. Biochem."},{"key":"58152_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 82, 3\u201318 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"58152_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg, S. R. et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).","journal-title":"N. Engl. J. Med."},{"key":"58152_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman, C. et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann. Rheum. Dis. 82, 119\u2013129 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"58152_CR22","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ard.2025.08.028","volume":"85","author":"JT Giles","year":"2026","unstructured":"Giles, J. T. et al. Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease. Ann. Rheum. Dis. 85, 103\u2013113 (2026).","journal-title":"Ann. Rheum. Dis."},{"key":"58152_CR23","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/art.43188","volume":"77","author":"R Aymon","year":"2025","unstructured":"Aymon, R. et al. Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries. Arthritis Rheumatol. 77, 1194\u20131204 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"58152_CR24","doi-asserted-by":"crossref","unstructured":"Prevoo, M. L., van 't Hof, M. A., Kuper, H. H., van Leeuwen, M. A., van de Putte, L. B., and van Riel, P. L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38, 44\u201348. (1995).","DOI":"10.1002\/art.1780380107"},{"key":"58152_CR25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/rheumatology\/keae192","volume":"64","author":"AG Dedemadi","year":"2025","unstructured":"Dedemadi, A. G. et al. Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment. Rheumatology (Oxford) 64, 648\u2013657 (2025).","journal-title":"Rheumatology (Oxford)"},{"key":"58152_CR26","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.1074\/jbc.M205232200","volume":"278","author":"A Chroni","year":"2003","unstructured":"Chroni, A. et al. The central helices of apoA-I can promote ATP-binding cassette transporter A1 (ABCA1)-mediated lipid efflux. Amino acid residues 220\u2013231 of the wild-type apoA-I are required for lipid efflux in vitro and high density lipoprotein formation in vivo. J. Biol. Chem. 278, 6719\u20136730 (2003).","journal-title":"J. Biol. Chem."},{"key":"58152_CR27","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00018-020-03583-y","volume":"78","author":"C Gkolfinopoulou","year":"2021","unstructured":"Gkolfinopoulou, C. et al. Structure-function analysis of naturally occurring apolipoprotein A-I L144R, A164S and L178P mutants provides insight on their role on HDL levels and cardiovascular risk. Cell. Mol. Life Sci. 78, 1523\u20131544 (2021).","journal-title":"Cell. Mol. Life Sci."},{"key":"58152_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11306-016-1157-8","volume":"13","author":"SB Breitkopf","year":"2017","unstructured":"Breitkopf, S. B. et al. A relative quantitative positive\/negative ion switching method for untargeted lipidomics via high resolution LC-MS\/MS from any biological source. Metabolomics 13, 30 (2017).","journal-title":"Metabolomics"},{"key":"58152_CR29","doi-asserted-by":"publisher","first-page":"8324","DOI":"10.1021\/ac061390w","volume":"78","author":"P Haimi","year":"2006","unstructured":"Haimi, P., Uphoff, A., Hermansson, M. & Somerharju, P. Software tools for analysis of mass spectrometric lipidome data. Anal. Chem. 78, 8324\u20138331 (2006).","journal-title":"Anal. Chem."},{"key":"58152_CR30","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1194\/jlr.S120001025","volume":"61","author":"G Liebisch","year":"2020","unstructured":"Liebisch, G. et al. Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures. J. Lipid Res. 61, 1539\u20131555 (2020).","journal-title":"J. Lipid Res."},{"key":"58152_CR31","doi-asserted-by":"publisher","first-page":"e011792","DOI":"10.1161\/JAHA.118.011792","volume":"8","author":"PJ Meikle","year":"2019","unstructured":"Meikle, P. J. et al. HDL phospholipids, but not cholesterol distinguish acute coronary syndrome from stable coronary artery disease. J. Am. Heart Assoc. 8, e011792 (2019).","journal-title":"J. Am. Heart Assoc."},{"key":"58152_CR32","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jacl.2023.07.003","volume":"17","author":"M Darabi","year":"2023","unstructured":"Darabi, M. et al. Integrated omics approach for the identification of HDL structure-function relationships in PCSK9-related familial hypercholesterolemia. J. Clin. Lipidol. 17, 643\u2013658 (2023).","journal-title":"J. Clin. Lipidol."},{"key":"58152_CR33","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1161\/ATVBAHA.113.301468","volume":"33","author":"L Camont","year":"2013","unstructured":"Camont, L. et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: Relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol. 33, 2715\u20132723 (2013).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"58152_CR34","doi-asserted-by":"publisher","first-page":"1254753","DOI":"10.3389\/fimmu.2023.1254753","volume":"14","author":"J Yan","year":"2023","unstructured":"Yan, J. et al. Dyslipidemia in rheumatoid arthritis: the possible mechanisms. Front. Immunol. 14, 1254753 (2023).","journal-title":"Front. Immunol."},{"key":"58152_CR35","doi-asserted-by":"publisher","first-page":"e0164564","DOI":"10.1371\/journal.pone.0164564","volume":"11","author":"JY Kim","year":"2016","unstructured":"Kim, J. Y. et al. Patients with rheumatoid arthritis show altered lipoprotein profiles with dysfunctional high-density lipoproteins that can exacerbate inflammatory and atherogenic process. PLoS ONE 11, e0164564 (2016).","journal-title":"PLoS ONE"},{"key":"58152_CR36","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1136\/heartjnl-2015-308953","volume":"103","author":"F O'Neill","year":"2017","unstructured":"O\u2019Neill, F. et al. Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis. Heart 103, 766\u2013773 (2017).","journal-title":"Heart"},{"key":"58152_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/MOL.0000000000000256","volume":"27","author":"MJ Ormseth","year":"2016","unstructured":"Ormseth, M. J. & Stein, C. M. High-density lipoprotein function in rheumatoid arthritis. Curr. Opin. Lipidol. 27, 67\u201375 (2016).","journal-title":"Curr. Opin. Lipidol."},{"key":"58152_CR38","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1136\/annrheumdis-2015-207872","volume":"75","author":"C Gabay","year":"2016","unstructured":"Gabay, C. et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 75, 1806\u20131812 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"58152_CR39","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/art.39039","volume":"67","author":"N Ronda","year":"2015","unstructured":"Ronda, N. et al. Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis Rheumatol. 67, 1155\u20131164 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"58152_CR40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jacl.2025.02.013","volume":"19","author":"EE Botta","year":"2025","unstructured":"Botta, E. E. et al. Modifications on lipid profile and high-density lipoprotein function related to treatment with tofacitinib in female patients with rheumatoid arthritis: Impact of previous therapy with biological agents. J. Clin. Lipidol. 19, 659\u2013669 (2025).","journal-title":"J. Clin. Lipidol."},{"key":"58152_CR41","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3899\/jrheum.2023-0112","volume":"50","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman, C. et al. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J. Rheumatol. 50, 1573\u20131580 (2023).","journal-title":"J. Rheumatol."},{"key":"58152_CR42","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1111\/bph.13932","volume":"174","author":"S Perez-Baos","year":"2017","unstructured":"Perez-Baos, S. et al. Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis. Br. J. Pharmacol. 174, 3018\u20133031 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"58152_CR43","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.bbrc.2017.06.020","volume":"490","author":"Z Wang","year":"2017","unstructured":"Wang, Z. et al. Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice. Biochem. Biophys. Res. Commun. 490, 194\u2013201 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"58152_CR44","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1161\/ATVBAHA.115.305504","volume":"35","author":"AP Agarwala","year":"2015","unstructured":"Agarwala, A. P. et al. High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease. Arterioscler. Thromb. Vasc. Biol. 35, 1515\u20131519 (2015).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"58152_CR45","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.bbalip.2015.05.007","volume":"1851","author":"F Rached","year":"2015","unstructured":"Rached, F. et al. Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A. Biochim. Biophys. Acta 1851, 1254\u20131261 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"58152_CR46","doi-asserted-by":"publisher","first-page":"e70028","DOI":"10.1096\/fba.2025-00010","volume":"7","author":"Y Wu","year":"2025","unstructured":"Wu, Y., Deng, Y., Angelov, B. & Angelova, A. Plasmalogen as a Bioactive Lipid Drug: From Preclinical Research Challenges to Opportunities in Nanomedicine. FASEB Bioadv. 7, e70028 (2025).","journal-title":"FASEB Bioadv."},{"key":"58152_CR47","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.atherosclerosis.2015.05.037","volume":"241","author":"I Sutter","year":"2015","unstructured":"Sutter, I. et al. Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL. Atherosclerosis 241, 539\u2013546 (2015).","journal-title":"Atherosclerosis"},{"key":"58152_CR48","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.atherosclerosis.2015.10.096","volume":"243","author":"AA Rasmiena","year":"2015","unstructured":"Rasmiena, A. A. et al. Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE\/GPx1-deficient mice. Atherosclerosis 243, 598\u2013608 (2015).","journal-title":"Atherosclerosis"},{"key":"58152_CR49","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.biochi.2023.09.004","volume":"215","author":"M Papin","year":"2023","unstructured":"Papin, M., Bouchet, A. M., Chantome, A. & Vandier, C. Ether-lipids and cellular signaling: A differential role of alkyl- and alkenyl-ether-lipids?. Biochimie 215, 50\u201359 (2023).","journal-title":"Biochimie"},{"key":"58152_CR50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.atherosclerosis.2017.06.925","volume":"263","author":"JV Moxon","year":"2017","unstructured":"Moxon, J. V. et al. Baseline serum phosphatidylcholine plasmalogen concentrations are inversely associated with incident myocardial infarction in patients with mixed peripheral artery disease presentations. Atherosclerosis 263, 301\u2013308 (2017).","journal-title":"Atherosclerosis"},{"key":"58152_CR51","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3390\/molecules25081925","volume":"25","author":"G Coliva","year":"2020","unstructured":"Coliva, G. et al. Sphingomyelins Prevent Propagation of Lipid Peroxidation-LC-MS\/MS Evaluation of Inhibition Mechanisms. Molecules 25, 1925 (2020).","journal-title":"Molecules"},{"key":"58152_CR52","doi-asserted-by":"publisher","first-page":"100307","DOI":"10.1016\/j.jlr.2022.100307","volume":"63","author":"M Holzer","year":"2022","unstructured":"Holzer, M. et al. HDL Isolated by Immunoaffinity, Ultracentrifugation, or Precipitation is Compositionally and Functionally Distinct. J. Lipid Res. 63, 100307 (2022).","journal-title":"J. Lipid Res."},{"key":"58152_CR53","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12944-017-0604-5","volume":"16","author":"C Qiu","year":"2017","unstructured":"Qiu, C., Zhao, X., Zhou, Q. & Zhang, Z. High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis. Lipids Health Dis. 16, 212 (2017).","journal-title":"Lipids Health Dis."},{"key":"58152_CR54","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.jacc.2011.08.030","volume":"58","author":"PJ Patel","year":"2011","unstructured":"Patel, P. J., Khera, A. V., Jafri, K., Wilensky, R. L. & Rader, D. J. The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J. Am. Coll. Cardiol. 58, 2068\u20132075 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"58152_CR55","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1002\/art.24677","volume":"60","author":"M McMahon","year":"2009","unstructured":"McMahon, M. et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis. Rheum. 60, 2428\u20132437 (2009).","journal-title":"Arthritis. Rheum."},{"key":"58152_CR56","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","volume":"3","author":"D Saleheen","year":"2015","unstructured":"Saleheen, D. et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: A prospective case-control study. Lancet Diabetes Endocrinol. 3, 507\u2013513 (2015).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"58152_CR57","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S0022-2275(20)31582-0","volume":"42","author":"M Navab","year":"2001","unstructured":"Navab, M. et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J. Lipid Res. 42, 1308\u20131317 (2001).","journal-title":"J. Lipid Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58152-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58152-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58152-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:06:59Z","timestamp":1790122019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-58152-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["58152"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-58152-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"29507"}}